Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18621418 | Means and Methods for the Determination of the Biological Activity of Neurotoxin Polypeptides in Cells | March 2024 | February 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18304934 | NOVEL BIOMARKER OF ACUTE CORONARY SYNDROMES | April 2023 | November 2024 | Abandon | 19 | 1 | 1 | No | No |
| 18050640 | APPLICATION OF THBS1 PROTEIN AND THBS3 PROTEIN AS BIOMARKERS FOR DETECTING ACUTE MYOCARDIAL INFARCTION | October 2022 | February 2025 | Abandon | 27 | 3 | 1 | No | No |
| 17848361 | BIOMARKER SIGNATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS AND USES THEREOF | June 2022 | October 2024 | Abandon | 28 | 0 | 1 | No | No |
| 17848365 | BIOMARKER SIGNATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS AND USES THEREOF | June 2022 | December 2024 | Abandon | 30 | 0 | 1 | No | No |
| 17830991 | METHOD OF EXOSOME ANALYSIS, REAGENT FOR EXOSOME ANALYSIS, AND ANALYZER FOR EXOSOME | June 2022 | February 2024 | Allow | 21 | 0 | 0 | Yes | No |
| 17740864 | CYTOCIDAL AGENT | May 2022 | September 2024 | Abandon | 28 | 1 | 2 | No | No |
| 17552578 | METHOD FOR THE DIAGNOSIS AND TREATMENT OF ESSENTIAL PRIMARY HYPERTENSION | December 2021 | June 2022 | Allow | 6 | 0 | 1 | Yes | No |
| 17544359 | MARKERS FOR ATRIAL FIBRILLATION (AF) | December 2021 | January 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17599399 | ANTI-NMDA RECEPTOR ANTIBODIES AND METHODS OF USE | September 2021 | September 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17336524 | SYSTEMS AND METHODS FOR DETECTING ANALYTES FROM CAPTURED SINGLE BIOLOGICAL PARTICLES | June 2021 | February 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17180616 | Methods and reagents for diagnosis of SARS-CoV-2 infection | February 2021 | December 2023 | Allow | 34 | 3 | 1 | Yes | No |
| 17153134 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | January 2021 | May 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17113684 | ANTI-VARIANT FC-REGION ANTIBODIES AND METHOD OF USE | December 2020 | December 2023 | Allow | 36 | 0 | 0 | Yes | No |
| 16763386 | MONOCLONAL ANTIBODY AND USE THEREOF | December 2020 | October 2023 | Allow | 41 | 0 | 0 | Yes | No |
| 16895169 | METHOD FOR PREDICTING THE RISK OF GETTING A MAJOR ADVERSE CARDIAC EVENT | June 2020 | January 2024 | Abandon | 44 | 1 | 0 | No | No |
| 16845403 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | April 2020 | November 2023 | Abandon | 43 | 0 | 1 | No | No |
| 16827145 | SENSITIVE DETECTION OF G-PROTEIN COUPLED RECEPTOR-ASSOCIATED SORTING PROTEIN 1 (GASP-1), GASP-1 MICROVESICLES, AND GASP-1 EXOSOMES | March 2020 | April 2024 | Abandon | 48 | 1 | 1 | No | No |
| 16806653 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | March 2020 | September 2024 | Allow | 55 | 2 | 1 | Yes | No |
| 16777241 | CAPTURE AND RELEASE OF PARTICLES FROM LIQUID SAMPLES | January 2020 | December 2023 | Allow | 47 | 1 | 1 | Yes | No |
| 16751831 | DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS USING OLIGONUCLEOTIDES ANTIGENS | January 2020 | August 2023 | Allow | 43 | 1 | 2 | Yes | No |
| 16711480 | CD8+T-CELL SUBSETS AS MARKERS FOR PREDICTION OF DELAYED FRACTURE HEALING | December 2019 | June 2022 | Allow | 30 | 0 | 0 | Yes | No |
| 16668005 | SYSTEM FOR BIODETECTION APPLICATIONS | October 2019 | August 2024 | Allow | 57 | 2 | 0 | Yes | No |
| 16555714 | METHOD OF MEASURING CHOLESTEROL LEVELS BY USING IMMUNOGENIC METHOD | August 2019 | January 2024 | Abandon | 53 | 2 | 0 | No | No |
| 16552876 | METHOD AND DEVICE FOR DETECTING SIGLEC12 | August 2019 | May 2024 | Abandon | 57 | 2 | 1 | No | No |
| 16546493 | In Vitro Diagnosis Device and Uses Thereof | August 2019 | March 2024 | Abandon | 55 | 2 | 1 | No | No |
| 16513818 | FLOW CYTOMETRY ASSAY METHODS | July 2019 | February 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16436700 | DETECTION OF AMNIOTIC FLUID IN VAGINAL SECRETIONS OF PREGNANT WOMEN DUE TO PREMATURE RUPTURE OF FETAL MEMBRANES | June 2019 | March 2022 | Allow | 33 | 0 | 0 | Yes | No |
| 16431979 | Immunoassay for Collagen Type VI | June 2019 | September 2022 | Allow | 40 | 0 | 1 | Yes | No |
| 16423060 | Glycosylation site-specific antibodies and anti-cancer compounds | May 2019 | March 2024 | Abandon | 57 | 1 | 1 | No | No |
| 16371432 | Protein Damage in Aging and Age-Related Diseases | April 2019 | November 2022 | Abandon | 44 | 2 | 1 | No | No |
| 16231193 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS | December 2018 | June 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16231188 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS | December 2018 | April 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16230482 | METHODS FOR EVALUATING RENAL INJURY AND RENAL FAILURE USING URINE LEVELS OF CHITINASE-3-LIKE PROTEIN 1 | December 2018 | February 2024 | Abandon | 60 | 3 | 2 | Yes | No |
| 16308258 | BIOMARKER SIGNATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS AND USES THEREOF | December 2018 | October 2022 | Abandon | 46 | 2 | 1 | No | No |
| 16308275 | BIOMARKER SIGNATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS AND USES THEREOF | December 2018 | October 2022 | Abandon | 46 | 2 | 1 | No | No |
| 16097791 | IDENTIFICATION AND MEDICAL APPLICATIONS OF ANTI-CITRULLINATED-PROTEIN ANTIBODIES IN RHEUMATOID ARTHRITIS | October 2018 | October 2024 | Allow | 60 | 3 | 2 | Yes | No |
| 16052454 | ANTIBODY-LINKED IMMUNO-SEDIMENTATION AGENT AND METHOD OF ISOLATING A TARGET FORM A SAMPLE USING SAME | August 2018 | May 2023 | Allow | 58 | 2 | 0 | Yes | Yes |
| 16040045 | ENZYME-LINKED IMMUNOASSAY TO DETECT FELIS CATUS GAMMAHERPESVIRUS 1 | July 2018 | September 2023 | Allow | 60 | 3 | 1 | Yes | No |
| 15988939 | Immunoassay for the determination of Fc-region modified antibodies | May 2018 | September 2022 | Allow | 52 | 2 | 1 | Yes | No |
| 15764531 | METHOD OF TREATMENT AND PROGNOSIS | March 2018 | November 2023 | Abandon | 60 | 5 | 1 | Yes | No |
| 15914099 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING HOST CELL PROTEIN IN CELL LINES AND RECOMBINANT POLYPEPTIDE PRODUCTS | March 2018 | July 2022 | Allow | 52 | 2 | 1 | Yes | No |
| 15746101 | HYDROPHILIC COATINGS OF PLASMONIC METALS TO ENABLE LOW VOLUME METAL-ENHANCED FLUORESCENCE | January 2018 | September 2022 | Allow | 56 | 2 | 1 | Yes | No |
| 15738498 | MEASURING FREQUENCY OF PATHOGEN-SPECIFIC T CELLS IN PERIPHERAL BLOOD | December 2017 | September 2022 | Allow | 57 | 2 | 1 | Yes | No |
| 15824905 | Methods and reagents for determining immunoglobulin gamma (IgG) antibody isotype concentration from biological samples | November 2017 | May 2023 | Allow | 60 | 3 | 1 | Yes | No |
| 15824761 | COMPOSITIONS AND METHODS FOR DIAGNOSING BREAST CANCER | November 2017 | June 2024 | Allow | 60 | 4 | 3 | Yes | No |
| 15573197 | Biomarkers for a Combination Therapy Comprising Lenvatinib and Everolimus | November 2017 | November 2022 | Abandon | 60 | 4 | 1 | Yes | No |
| 15547608 | DIAGNOSIS OF RISK OF UROTHELIAL CANCER | July 2017 | July 2020 | Abandon | 35 | 6 | 1 | No | No |
| 15547080 | IMMUNOASSAYS FOR HIGH POSITIVELY CHARGED PROTEINS | July 2017 | February 2023 | Abandon | 60 | 5 | 1 | No | No |
| 15544938 | COMPOUNDS AND METHODS FOR THE DETECTION OF CALPROTECTIN | July 2017 | November 2023 | Abandon | 60 | 4 | 1 | No | No |
| 15543465 | METHOD FOR PREPARING A BIOLOGICAL SAMPLE FOR USE IN AN IMMUNOLABELING PROCESS | July 2017 | October 2023 | Allow | 60 | 5 | 1 | Yes | Yes |
| 15524899 | ARTERIOSCLEROSIS AND CANCER DETECTION METHOD USING DEOXYHYPUSINE SYNTHASE GENE AS INDICATOR | May 2017 | May 2023 | Allow | 60 | 4 | 1 | Yes | Yes |
| 15469350 | A METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS | March 2017 | September 2023 | Allow | 60 | 7 | 1 | Yes | Yes |
| 15502652 | METHOD FOR DETECTING TARGET MOLECULE AND KIT FOR USE IN SAID METHOD | February 2017 | November 2022 | Abandon | 60 | 5 | 1 | Yes | No |
| 15309600 | METHOD FOR DETERMINATION OF VITELLOGENIN AS BIOMARKER FOR AN EXOGENOUS OESTROGENIC EFFECT ON FISH | January 2017 | January 2018 | Abandon | 14 | 0 | 1 | No | No |
| 15321564 | BIOCHEMICAL MARKERS FOR USE IN DETERMINING RISK OF DIABETES | December 2016 | April 2018 | Abandon | 15 | 0 | 1 | No | No |
| 15311169 | EARLY PLACENTA INSULIN-LIKE PEPTIDE (PRO-EPIL) | November 2016 | March 2018 | Abandon | 16 | 0 | 1 | No | No |
| 15306005 | MATERIALS AND METHODS FOR DIAGNOSIS OF PERI-IMPLANT BONE AND JOINT INFECTIONS USING PROPHENOLOXIDASE PATHWAY | October 2016 | March 2018 | Abandon | 17 | 0 | 1 | No | No |
| 15300194 | Mammalian Dickkopf 3 (DKK3) as Urinary Marker for Chronic Kidney Diseases | September 2016 | April 2018 | Abandon | 18 | 1 | 1 | No | No |
| 15128913 | ANTI-CHONDROITIN-SULFATE-E ANTIBODY | September 2016 | May 2017 | Allow | 8 | 0 | 0 | Yes | No |
| 15273815 | METHOD FOR DETECTING PROTEIN-PROTEIN INTERACTION | September 2016 | May 2017 | Allow | 7 | 0 | 0 | No | No |
| 15127475 | NEW MARKERS FOR THE ASSESSMENT OF THE RISK FOR DEVELOPMENT OF A CARDIOVASCULAR DISORDER | September 2016 | January 2025 | Abandon | 60 | 7 | 2 | Yes | No |
| 15228341 | Anti-p40 Antibodies Systems and Methods | August 2016 | February 2017 | Allow | 6 | 0 | 1 | Yes | No |
| 15226794 | Anti-Uroplakin II Antibodies Systems and Methods | August 2016 | July 2017 | Allow | 11 | 0 | 1 | Yes | No |
| 15215056 | AFLATOXIN NANOBODY IMMUNOABSORBENT AND IMMUNOAFFINITY COLUMN AND PREPARATION METHOD AND USE THEREOF | July 2016 | January 2017 | Allow | 6 | 0 | 0 | Yes | No |
| 15196718 | IL-6 DETECTION BASED EARLY DIAGNOSIS AND PREDICTION OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AND SEPSIS IN ASYMPTOMATIC PATIENTS | June 2016 | December 2022 | Allow | 60 | 7 | 1 | Yes | No |
| 15137982 | METHODS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE USING TREFOIL FACTOR 3 FAILURE | April 2016 | May 2017 | Abandon | 13 | 1 | 0 | Yes | No |
| 15065615 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING HOST CELL PROTEIN IN CELL LINES AND RECOMBINANT POLYPEPTIDE PRODUCTS | March 2016 | December 2017 | Allow | 21 | 0 | 1 | Yes | No |
| 14993883 | BIOMARKERS, METHODS AND KITS FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS | January 2016 | September 2017 | Abandon | 21 | 0 | 1 | No | No |
| 14901123 | Means and Methods for the determination of the biological activity of Neurotoxin polypeptides in cells | December 2015 | February 2024 | Allow | 60 | 6 | 1 | Yes | Yes |
| 14964410 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | December 2015 | September 2016 | Abandon | 9 | 1 | 0 | No | No |
| 14772853 | METHODS FOR DETECTING INFLAMMATORY DISORDERS | September 2015 | January 2018 | Abandon | 28 | 1 | 1 | No | No |
| 14839744 | Anti-p40 Antibodies Systems and Methods | August 2015 | April 2016 | Allow | 8 | 0 | 1 | Yes | No |
| 14818768 | MCAM AS A BIOMARKER FOR FLUID HOMEOSTASIS | August 2015 | January 2018 | Allow | 29 | 2 | 0 | Yes | No |
| 14764787 | METHOD FOR SUPPRESSING FALSE NEGATIVE IN IMMUNOASSAY FOR SPECIMEN DERIVED FROM BIOLOGICAL MUCOUS MEMBRANE | July 2015 | January 2018 | Abandon | 29 | 1 | 1 | No | No |
| 14810333 | Systems And Methods For Early Detection Of Cervical Cancer By Multiplex Protein Biomarkers | July 2015 | September 2017 | Abandon | 26 | 0 | 1 | No | No |
| 14803416 | IMMUNOCHROMATOGRAPHY DEVICES, METHODS, AND KITS | July 2015 | November 2017 | Allow | 28 | 1 | 1 | Yes | No |
| 14794273 | ANTIBODIES TO ARGININOSUCCINATE SYNTHASE AND RELATED METHODS | July 2015 | November 2017 | Allow | 28 | 1 | 1 | Yes | No |
| 14752282 | BIOMARKERS FOR RADIATION EXPOSURE | June 2015 | December 2022 | Abandon | 60 | 6 | 1 | No | No |
| 14713387 | BIOMARKERS OF ACUTE LIVER INJURY | May 2015 | December 2017 | Abandon | 31 | 1 | 1 | No | No |
| 14688010 | Charged Peptide Appendage to Facilitate Oriented Protein Covalent Immobilization | April 2015 | August 2017 | Allow | 28 | 2 | 1 | No | No |
| 14678213 | Methods for diagnosing pulmonary hypertension | April 2015 | January 2017 | Abandon | 22 | 1 | 0 | No | No |
| 14432132 | Anti-Uroplakin II Antibodies Systems and Methods | March 2015 | April 2016 | Allow | 13 | 0 | 0 | Yes | No |
| 14671355 | COMPOSITIONS AND METHODS RELATED TO DIAGNOSIS OF PROSTATE CANCER | March 2015 | May 2023 | Allow | 60 | 6 | 2 | Yes | No |
| 14667378 | IMMUNOSORBENT AND IMMUNOAFFINITY COLUMN FOR AFLATOXIN M1 NANOBODY AND PREPARATION METHOD THEREOF | March 2015 | April 2016 | Allow | 12 | 0 | 0 | Yes | No |
| 14667206 | AFLATOXIN M1 NANOBODY 2014AFM-G2 | March 2015 | June 2015 | Allow | 3 | 0 | 0 | Yes | No |
| 14666869 | HYBRIDOMA CELL LINE ST03, MONOCLONAL ANTIBODY AGAINST AFLATOXIN BIOSYNTHETIC PRECURSOR STERIGMATOCYSTIN AND USE THEREOF | March 2015 | July 2015 | Allow | 3 | 0 | 0 | Yes | No |
| 14630739 | METHOD OF DIAGNOSING KIDNEY DAMAGE IN DIABETIC PATIENTS USING URINARY CD36 AS A BIOMARKER | February 2015 | February 2018 | Abandon | 35 | 2 | 1 | No | No |
| 14419223 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | February 2015 | January 2017 | Abandon | 23 | 0 | 1 | No | No |
| 14573686 | COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT | December 2014 | January 2017 | Abandon | 25 | 0 | 1 | No | No |
| 14574209 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | December 2014 | November 2015 | Abandon | 11 | 1 | 1 | No | No |
| 14570194 | METHOD OF PROGNOSIS | December 2014 | August 2015 | Abandon | 8 | 1 | 0 | No | No |
| 14529994 | IMMUNOASSAY STANDARDS AND MEASUREMENT OF CLINICAL BIOMARKERS USING INTRA-ASSAY CALIBRATION STANDARDS | October 2014 | June 2016 | Allow | 20 | 0 | 1 | Yes | No |
| 14506461 | METHOD OF PREDICTING ACUTE APPENDICITIS | October 2014 | November 2017 | Allow | 37 | 2 | 1 | Yes | No |
| 14345176 | METHOD FOR DETERMINING THE GLYCOSYLATION OF AN ANTIBODY | October 2014 | September 2017 | Allow | 42 | 2 | 1 | Yes | No |
| 14500849 | BLOCKING REAGENT COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | September 2014 | June 2017 | Allow | 33 | 1 | 2 | Yes | No |
| 14382870 | MEANS AND METHODS FOR ASSESSING DISORDERS RELATED TO IMPAIRED IRON ADSORPTION OR ENERGY METABOLISM | September 2014 | November 2017 | Abandon | 38 | 2 | 1 | No | No |
| 14381549 | METHODS FOR EVALUATING RENAL INJURY AND RENAL FAILURE USING URINE LEVELS OF CHITINASE-3-LIKE PROTEIN 1 | August 2014 | November 2017 | Abandon | 39 | 1 | 1 | Yes | No |
| 14379572 | MEANS AND METHODS FOR ASSESSING LIVER DISORDERS | August 2014 | December 2016 | Abandon | 28 | 1 | 2 | No | No |
| 14376921 | MEANS AND METHODS FOR ASSESSING AN ENDOCRINE DISEASE OR DISORDER | August 2014 | December 2016 | Abandon | 28 | 1 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BELEI, CARMENCITA.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BELEI, CARMENCITA works in Art Unit 1678 and has examined 226 patent applications in our dataset. With an allowance rate of 42.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner BELEI, CARMENCITA's allowance rate of 42.5% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BELEI, CARMENCITA receive 2.00 office actions before reaching final disposition. This places the examiner in the 65% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BELEI, CARMENCITA is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +67.3% benefit to allowance rate for applications examined by BELEI, CARMENCITA. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.6% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.2% of cases where such amendments are filed. This entry rate is in the 22% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 70.0% of appeals filed. This is in the 51% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 58.5% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.3% of allowed cases (in the 72% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.